AGTC Announces Updated Development Plan for Its X-Linked Retinitis Pigmentosa Clinical Program

UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced next steps in the clinical development of the company’s potential treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in … Continue reading AGTC Announces Updated Development Plan for Its X-Linked Retinitis Pigmentosa Clinical Program